This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Evkeeza industry.
What is the projected value of the evkeeza market by 2029?
The evkeeza market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to the imposition of supportive regulations and policies, rapid advances in genomics and personalized medicine, an aging population, favorable government policies, and the emergence of situations like birth defects.
The evkeeza market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to the rise in the prevalence of hypercholesterolemia, the rising prevalence of rare diseases across the globe, the growing burden of rare neurological diseases, and increasing healthcare expenditure. Major trends in the forecast period include the development of specialized medications, personalized medicine, telemedicine and remote monitoring, the expansion of patient support programs, and regulatory approvals.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20070&type=smp
How are technological advancements fueling growth in the evkeeza market?
The increasing prevalence of genetic disorders is anticipated to drive the growth of the evkeeza market in the future. Genetic disorders are diseases or conditions caused by abnormalities in an individual’s DNA, which can result from mutations in one or more genes or changes in the structure or number of chromosomes. The rise in genetic disorders is due to improved diagnostic technologies and increased environmental factors that contribute to genetic conditions. Evkeeza is used to treat homozygous familial hypercholesterolemia (HoFH), a genetic disorder, by inhibiting ANGPTL3 to lower LDL cholesterol levels in patients with this condition. For instance, in June 2024, according to the American Society of Hematology, a US-based non-profit organization, by 2050, the global population of individuals with sickle cell disease (SCD) is projected to grow by approximately 30 percent. Therefore, rising genetic disorders are driving the growth of the evkeeza market.
Which segment currently leads the evkeeza market in terms of revenue share?
The evkeeza market covered in this report is segmented –
1) By Indication: Primary Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
2) By Route Of Administration: Intravenous (IV) Infusion, Self-Administration, Subcutaneous (SC) Administration, Hospital Infusion Centers, Infusion In Ambulatory Care Settings
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/evkeeza-global-market-report
What technological trends are expected to redefine the evkeeza market?
The key trend in the evkeeza market is obtaining regulatory approvals for drugs to expand its reach and solidify its position in the treatment of patients with homozygous familial hypercholesterolemia (HoFH). Regulatory approvals refer to the formal authorization granted by governmental or regulatory bodies for a drug, medical device, or treatment to be marketed and used by the public. For instance, in March 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received FDA approval for Evkeeza (evinacumab-dgnb) for young children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder causing extremely high LDL cholesterol levels. This marks the first approval of an ANGPTL3 inhibitor for this age group, providing a new treatment option for approximately 1,300 affected individuals in the U.S. Clinical trials showed that children treated with evkeeza alongside other lipid-lowering therapies experienced an average 48% reduction in LDL-C levels after 24 weeks.
Who are the top competitors in the global evkeeza market?
Major companies operating in the evkeeza market include Regeneron Pharmaceuticals Inc.
What regional dynamics are shaping the future of the global evkeeza market?
North America was the largest region in the evkeeza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the evkeeza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Can Companies Use The Evkeeza Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20070
Need Customized Data On Evkeeza Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20070&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
